Published in Eur Heart J on May 25, 2015
Universal Familial Hypercholesterolemia Screening in Children | NCT04507984
PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era. Curr Opin Lipidol (2015) 0.93
Diverse etiology of hyperlipidemia among hospitalized children in Western region of Saudi Arabia. Saudi Med J (2016) 0.84
Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council. Arterioscler Thromb Vasc Biol (2015) 0.83
Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res (2016) 0.83
PCSK9 Inhibitors: A Technology Worth Paying For? Pharmacoeconomics (2016) 0.81
Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. Circ Cardiovasc Genet (2016) 0.81
The year in cardiology 2015: prevention. Eur Heart J (2016) 0.79
My Approach to the Patient With Familial Hypercholesterolemia. Mayo Clin Proc (2016) 0.78
Temporal trends in lipid screening and therapy among youth from 2002 to 2012. J Clin Lipidol (2015) 0.77
Identification and Treatment of Patients with Homozygous Familial Hypercholesterolaemia: Information and Recommendations from a Middle East Advisory Panel. Curr Vasc Pharmacol (2015) 0.77
Improving detection of familial hypercholesterolaemia in primary care using electronic audit and nurse-led clinics. J Eval Clin Pract (2015) 0.77
The genetics and screening of familial hypercholesterolaemia. J Biomed Sci (2016) 0.76
Genetic testing of familial hypercholesterolemia in a real clinical setting. Wien Klin Wochenschr (2016) 0.76
Optimizing Treatment of Familial Hypercholesterolemia in Children and Adolescents. Curr Cardiol Rep (2015) 0.75
Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders. Vasc Health Risk Manag (2016) 0.75
Update on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel Therapeutics. Endocrinol Metab (Seoul) (2017) 0.75
Relation between Liver Transaminases and Dyslipidaemia among 2-10 y.o. Northern Mexican Children. PLoS One (2016) 0.75
CCC- and WASH-mediated endosomal sorting of LDLR is required for normal clearance of circulating LDL. Nat Commun (2016) 0.75
Screening for Familial Hypercholesterolemia in Children: What Can We Learn From Adult Screening Programs? Healthcare (Basel) (2015) 0.75
Hypercholesterolaemia: optimal treatment by next-generation drugs? Neth Heart J (2015) 0.75
Time to improve statin prescription guidelines in low-risk patients? Eur J Prev Cardiol (2017) 0.75
Atypical Presentation and Treatment Response in a Child with Familial Hypercholesterolemia Having a Novel LDLR Mutation. JIMD Rep (2016) 0.75
Clinical Application of Genetic Testing in Heart Failure. Curr Heart Fail Rep (2017) 0.75
A receptor-mediated pathway for cholesterol homeostasis. Science (1986) 19.28
Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med (1998) 15.09
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J (2011) 10.52
Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med (2007) 7.96
Role of oxidative modifications in atherosclerosis. Physiol Rev (2004) 6.73
Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol (2012) 4.56
Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest (2003) 4.42
Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J (2010) 4.31
Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet (2013) 3.87
Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. BMJ (2007) 3.64
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA (2004) 3.55
Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature (2014) 3.29
Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation (1974) 3.29
Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association. Hypertension (2009) 3.22
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet (2014) 2.91
Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ (2002) 2.55
The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. Eur Heart J (2011) 2.43
Carotid intima-media thickness in children with familial hypercholesterolemia. Circ Res (2013) 2.15
Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation (2007) 2.15
Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Circulation (2008) 2.11
Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol (2002) 2.09
Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol (2013) 2.01
Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis (2013) 1.88
Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. Circulation (2015) 1.85
Curing atherosclerosis should be the next major cardiovascular prevention goal. J Am Coll Cardiol (2014) 1.81
Genetic testing in asymptomatic minors: Recommendations of the European Society of Human Genetics. Eur J Hum Genet (2009) 1.80
Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest (1994) 1.72
Vascular calcifications in homozygote familial hypercholesterolemia. Arterioscler Thromb Vasc Biol (2008) 1.67
Molecular basis of autosomal dominant hypercholesterolemia: assessment in a large cohort of hypercholesterolemic children. Circulation (2011) 1.65
Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia. J Am Coll Cardiol (2014) 1.64
Detection and quantitation of calcific atherosclerosis by ultrafast computed tomography in children and young adults with homozygous familial hypercholesterolemia. Arterioscler Thromb (1994) 1.58
Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am J Clin Nutr (2005) 1.57
Risk scores predict atherosclerotic lesions in young people. Arch Intern Med (2005) 1.56
Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment. Ann Hum Genet (2012) 1.53
Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation (2011) 1.51
Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr (2009) 1.49
Implementation of lipid screening guidelines in children by primary pediatric providers. J Pediatr (2013) 1.47
Positive screening and carrier results for the England-wide universal newborn sickle cell screening programme by ethnicity and area for 2005-07. J Clin Pathol (2010) 1.41
A double-blind randomized trial of fish oil to lower triglycerides and improve cardiometabolic risk in adolescents. J Pediatr (2014) 1.40
Use of targeted exome sequencing as a diagnostic tool for Familial Hypercholesterolaemia. J Med Genet (2012) 1.29
Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin Genet (2010) 1.29
Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J (2014) 1.26
Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol (2008) 1.26
Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin Chem Lab Med (2008) 1.25
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol (2011) 1.22
A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol (2007) 1.22
Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother (2009) 1.20
Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis (2008) 1.16
Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb (2012) 1.16
Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart (2011) 1.15
Cellular pathology of homozygous familial hypercholesterolemia. Am J Pathol (1979) 1.15
Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med (2014) 1.12
Universal versus targeted blood cholesterol screening among youth: The CARDIAC project. Pediatrics (2010) 1.10
Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol (2011) 1.09
Familial hypercholesterolaemia: a model of care for Australasia. Atheroscler Suppl (2011) 1.04
Advances in genetics show the need for extending screening strategies for autosomal dominant hypercholesterolaemia. Eur Heart J (2012) 0.99
Arterial endothelial function and wall thickness in familial hypercholesterolemia and familial combined hyperlipidemia and the effect of statins. A systematic review and meta-analysis. Atherosclerosis (2010) 0.98
Trans fatty acids and cardiovascular health: research completed? Eur J Clin Nutr (2013) 0.97
Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia. Curr Med Res Opin (2010) 0.96
Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. JAMA (2014) 0.95
Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. Semin Vasc Med (2004) 0.95
Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol (2011) 0.95
Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry. Am Heart J (2013) 0.95
Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol (2011) 0.95
Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia. Atherosclerosis (2006) 0.95
Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis (2011) 0.94
Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Community Genet (2008) 0.93
Homozygous familial hypercholesterolaemia. Lancet (2012) 0.93
Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol (2008) 0.92
Usefulness of electron beam tomography in adolescents and young adults with heterozygous familial hypercholesterolemia. Circulation (1998) 0.92
Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol (2011) 0.91
Garlic extract therapy in children with hypercholesterolemia. Arch Pediatr Adolesc Med (1998) 0.91
Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev (2014) 0.91
APOE p.Leu167del mutation in familial hypercholesterolemia. Atherosclerosis (2013) 0.90
Functionality of sequence variants in the genes coding for the low-density lipoprotein receptor and apolipoprotein B in individuals with inherited hypercholesterolemia. Hum Mutat (2010) 0.90
Pregnancy outcomes in familial hypercholesterolemia: a registry-based study. Circulation (2011) 0.90
Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. J Clin Lipidol (2014) 0.90
Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers. Atherosclerosis (2014) 0.90
Effect of docosahexaenoic acid on lipoprotein subclasses in hyperlipidemic children (the EARLY study). Am J Cardiol (2005) 0.89
Family history and cardiovascular risk in familial hypercholesterolemia: data in more than 1000 children. Circulation (2003) 0.89
Paediatric screening for hypercholesterolaemia in Europe. Arch Dis Child (2011) 0.88
Management of familial hypercholesterolemia in children and adolescents. Position paper of the Polish Lipid Expert Forum. J Clin Lipidol (2014) 0.88
Premature atherosclerosis is not systematic in phytosterolemic patients: severe hypercholesterolemia as a confounding factor in five subjects. Atherosclerosis (2014) 0.88
Markers of atherosclerotic development in children with familial hypercholesterolemia: a literature review. Atherosclerosis (2014) 0.87
What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia? Curr Opin Lipidol (2008) 0.87
Statin treatment of children with familial hypercholesterolemia--trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus? Atherosclerosis (2012) 0.87
Pregnancy in women suffering from familial hypercholesterolemia: a harmful period for both mother and newborn? Curr Opin Lipidol (2009) 0.86
Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia. Curr Opin Lipidol (2010) 0.85
Cohort Profile: the STRIP Study (Special Turku Coronary Risk Factor Intervention Project), an Infancy-onset Dietary and Life-style Intervention Trial. Int J Epidemiol (2008) 0.85
Universal screening of cholesterol in children. Clin Cardiol (2012) 0.85
Plant sterol ester-enriched spread lowers plasma total and LDL cholesterol in children with familial hypercholesterolemia. Am J Clin Nutr (2002) 0.84
The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial. Atherosclerosis (2015) 0.84
Plant sterols lower LDL cholesterol without improving endothelial function in prepubertal children with familial hypercholesterolaemia. J Inherit Metab Dis (2003) 0.83
Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J (2010) 4.31
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol (2013) 2.60
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J (2015) 1.92
Framingham score and LV mass predict events in young adults: CARDIA study. Int J Cardiol (2014) 0.86
Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. Cancer Res (2017) 0.83
Acidification of the intimal fluid: the perfect storm for atherogenesis. J Lipid Res (2014) 0.81
Potential pathological roles for oxidized low-density lipoprotein and scavenger receptors SR-AI, CD36, and LOX-1 in aortic valve stenosis. Atherosclerosis (2014) 0.81
The impact of mast cells on cardiovascular diseases. Eur J Pharmacol (2015) 0.78
Enhanced vascular permeability facilitates entry of plasma HDL and promotes macrophage-reverse cholesterol transport from skin in mice. J Lipid Res (2014) 0.77
Activated human mast cells induce LOX-1-specific scavenger receptor expression in human monocyte-derived macrophages. PLoS One (2014) 0.76
Spatial distributions of lipids in atherosclerosis of human coronary arteries studied by time-of-flight secondary ion mass spectrometry. Am J Pathol (2015) 0.76
Initiation of PCSK9 inhibition in patients with heterozygous familial hypercholesterolaemia entering adulthood: a new design for living with a high-risk condition? Eur Heart J (2016) 0.76
Sex differences in the associations of visceral adiposity, homeostatic model assessment of insulin resistance, and body mass index with lipoprotein subclass analysis in obese adolescents. J Clin Lipidol (2016) 0.75
Atherosclerosis: Is a cure in sight? J Clin Lipidol (2015) 0.75
Statistical vs clinical significance: a matter of debate for orlistat treatment. Pharmacol Res (2017) 0.75
HDL abnormalities in familial hypercholesterolemia: Focus on biological functions. Prog Lipid Res (2017) 0.75
Phytosterol-mediated inhibition of intestinal cholesterol absorption in mice is independent of liver X receptor. Mol Nutr Food Res (2017) 0.75
Rescue therapy with PCSK9 inhibitors for patients with delayed diagnosis of heterozygous familial hypercholesterolemia: Redressing the balance of missed opportunities. J Clin Lipidol (2016) 0.75
HDL functionality in familial hypercholesterolemia: effects of treatment modalities and pharmacological interventions. Drug Discov Today (2017) 0.75
Life-threatening coronary disease is prevalent in patients with stenosing carotid artery disease. Int J Stroke (2015) 0.75
Effect of orlistat on plasma lipids and body weight: a systematic review and meta-analysis of 33 randomized controlled trials. Pharmacol Res (2017) 0.75
Combination of intracerebral haemorrhage and familial hypercholesterolemia in the acute hospital setting--a challenge for statin treatment? Int J Stroke (2015) 0.75